2381 Results for "

monoblastic leukemia

" in MedChemExpress (MCE) Product Catalog:

Products (2381)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

669

ML385

669 Publications Verification

Cat. No.: HY-100523

CAS No.: 846557-71-9

Purity: 99.96%

Target:

Keap1-Nrf2 Ferroptosis Apoptosis mTOR

Research Areas:

Cardiovascular Disease Cancer

ML385 is a potent and selective Nrf2 inhibitor with an IC₅₀ of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

166

Navitoclax dihydrochloride

166 Cited Publications

Cat. No.: HY-10087A1

CAS No.: 1093851-28-5

Synonyms: ABT-263 dihydrochloride

Target:

Bcl-2 Family Apoptosis Survivin TGF-β Receptor

Research Areas:

Cardiovascular Disease Cancer

Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a K_i value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .

Compare